Toward Optimal Treatment in Women: The Effect of Sex on Metoprolol‐Diphenhydramine Interaction
- 1 February 2010
- journal article
- research article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 50 (2) , 214-225
Abstract
The objective of this study was to determine if sex influences the pharmacokinetics and hemodynamics of the CYP2D6 substrate metoprolol and its interaction with diphenhydramine (CYP2D6 inhibitor) in healthy young participants with high (extensive metabolizer [EM]) or low (poor metabolizer [PM]) CYP2D6 activities. A prespecified comparative analysis of data from 2 sequential clinical trials that included 16 EM and 4 PM women and 10 EM and 6 PM men was performed. The participants in the 2 trials were administered a single oral dose of 100 mg metoprolol in the presence of steady‐state diphenhydramine or placebo. Serial plasma and urine samples were obtained for 48 hours, and hemodynamic data was obtained for 12 hours after metoprolol. In the placebo arm, EM and PM women had 62% and 59% higher S‐metoprolol AUC0–∞and 26% and 71% lower CL/F, respectively, compared to men with the same phenotype (all Ps < .05 women compared to men). These differences dissipated on body weight (WT) correction. Women (especially PMs) experienced greater negative chronotropic effects of metoprolol than men (P < .0001 women compared to men). Diphenhydramine coadministration increased S‐metoprolol AUC by 84% in EM women and 45% in EM men (P < .009 women compared to men). In the diphenhydramine arm, sex differences in pharmacokinetics persisted even after WT correction, resulting in greater negative chronotropic effects in women (all Ps < .05 women compared to men). Metoprolol dose should be adjusted for body weight, particularly in women. Coadministration of a CYP2D6 inhibitor such as diphenhydramine, by a patient at similar doses in the 2 sexes, could result in a greater inhibition of clearance of CYP2D6 substrates with a resulting higher risk of pronounced pharmacological and adverse effects in women compared to men.Keywords
This publication has 17 references indexed in Scilit:
- Expression and Functional Analysis of CYP2D6.24, CYP2D6.26, CYP2D6.27, and CYP2D7 IsozymesDrug Metabolism and Disposition, 2009
- Modulation of Metoprolol Pharmacokinetics and Hemodynamics by Diphenhydramine Coadministration during Exercise Testing in Healthy Premenopausal WomenThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Significant interaction between the nonprescription antihistamine diphenhydramine and the CYP2D6 substrate metoprolol in healthy men with high or low CYP2D6 activityClinical Pharmacology & Therapeutics, 2000
- Gender‐Specific Effects on Verapamil Pharmacokinetics and Pharmacodynamics in HumansThe Journal of Clinical Pharmacology, 2000
- Site Dependence of Drug Concentrations in Postmortem Blood—A Case Study*Journal of Analytical Toxicology, 1987
- Influence of smoking and gender on the disposition kinetics of metoprololEuropean Journal of Clinical Pharmacology, 1987
- Quantitative analysis of metoprolol and three of its metabolites in urine and liver microsomes by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1985
- Determination of two metoprolol metabolises in human urine by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1984
- Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizersClinical Pharmacology & Therapeutics, 1983
- Metabolism of metoprolol‐(3H) in man, the dog and the ratActa Pharmacologica et Toxicologica, 1975